drugset / Trial / NCT07062328
A Trial of Recaticimab and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable BTC
Phase 2
Not yet recruiting
39 enrolled
Sun Yat-sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The study aims to evaluate the efficacy and safety of Recaticimab and Adebrelimab in Combination With chemotherapy in patients with metastatic biliary tract carcinoma (BTC).
Timeline
- Start
- 2025-07-10
- Primary completion
- 2026-12-10
- Completion
- 2028-04-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Recaticimab | Monoclonal antibody | 150 mg | Subcutaneous |
| Background | Cisplatin | Other / unclassified | 25 mg/m2 | — |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |